The new information will be shared via posters at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress taking place July 10-12.
The highlights include:
- A preclinical study evaluating the plant-based cucumber mosaic virus-like-particle used in the group’s peanut allergy vaccine candidate due to enter the clinic in 2022.
- A retrospective cohort study, intending to reflect real-world conditions that used prescription data from patients in Germany to assess the impact of its grass or tree pollen immunotherapy.
- Three approaches examining the tolerability of, and impact on allergy symptoms from, ImmunoBON, the group’s protein-based oral allergy product.
Chief executive Manuel Llobet said: “Our research programmes are going beyond symptom management, to focus on directly treating the cause of allergy.
“The research that we’re delighted to be sharing with research colleagues at this year’s EAACI congress demonstrates the strength of our science and our commitment to developing novel, short-course immunotherapies that can help patients to change the way they think about their allergies and better manage their conditions.”